The immune system is a pervasive network of molecular mediators, cells, tissues, and organs with central relevance in human health. Importantly, immunotherapy designed to modulate the activity of CD8 or CD4 T cell lymphocytes is a promising and increasingly relevant pillar for cancer treatment. 1 T cells recognize epitopes in the context of human leukocyte antigen (HLA) molecules that are highly diverse and have a broad but finetuned capacity of binding non-self-peptides to contribute for appropriate immune responses. The search for the motifs responsible for the binding of peptides to HLA molecules started several decades ago but the discovered complexity of HLA-peptide interactions prompted continuous development, namely using in silico approaches and artificial intelligence. Machine learning (ML) is a fundamental branch of artificial intelligence, which can be defined as a set of models and respective induction algorithms, able to learn complex relationships or patterns from empirical data and capable of making accurate decisions. Thus, ML intends to train models from large amounts of data, through specific algorithms that give the machine the ability to learn how to perform a specific task from data without being explicitly programmed. This approach can be used to analyse, interpret and predict the outcomes for unseen data, achieving results that would not be possible in many cases through conventional statistics. ML has several applications in medicine, including the field of immunoinformatics, which focuses on the in silico analysis and modelling of immunological data and problems. Immunoinformatics applications are growing and, consequently, are becoming more important to immunological research. 2 Experimental HLA-binding assays require synthesis and testing of overlapping peptides, including the full-length sequences of interest, which on a large-scale is an expensive and time-consuming laboratorial task. The primary objective of immunoinformatics research is to design efficient algorithms for the mapping of potential B cell and T cell epitopes. These tools can determine the sequence regions with potential binding sites, which in turn accelerates the development of novel immunotherapies. 3 These methods were developed using models such as artificial neural networks (ANNs). 4 ANNs are one of the main ML models, providing a computational approach mimicking the information processing of the brain. These models can be used to solve problems of classification or regression. 5 Their architecture is composed of a set of 'artificial neurons' distributed in layers: the input layer receiving the initial data, the hidden or intermediate layer(s) that are responsible for extracting the patterns associated with the data, and the output layer, which presents the final result of the process. The learning capability is one of the most important characteristics of neural networks. Thus, from a sample, the neural network learns the relationship between the inputs and outputs and can produce solutions for any new example. The learning process consists of a gradientdescent based algorithm that iteratively changes the synaptic weights associated with the neurons of the network seeking to minimize a given cost function, typically based on an error metric (loss function) computed over the training examples. 5 
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Currently, several ML-based epitope prediction tools are available. The Immune Epitope Database and Analysis Resource (IEDB) is a widely used resource hosting a database of experimentally validated epitopes and tools for de novo prediction. NetMHCpan 6 and NetMHCIIpan 7 are two tools that generate quantitative predictions of peptide binding affinity to class I and class II HLAs, respectively. NetMHCpan and NetMHCIIpan have high accuracy in available datasets but are closed source software with limited licence user agreements. MHCflurry 8 is an ensemble of HLA class I allele-specific predictors, whose accuracy, implementation, and open-source licencing makes it very attractive for large-scale epitope prediction studies. Another ML-based class I HLA prediction method is MHCnuggets 9 , which uses gated-recurrent ANNs to process sequences directly and handle peptides of any length without artificial lengthening or shortening. Similarly, needed improvements in class II epitope prediction tools are in development with tools such as MixMHC2pred. 10 Despite of its immense potential, successful ML-based approaches are highly dependent on the datasets available for training and testing. 11 The datasets of validated T cell epitopes found in databases are almost entirely formed of epitopes from bacteria or viruses and were not obtained by standardized experimental methodologies. Improvements in the available epitope datasets will likely boost the performance of ML-based predictors and facilitate tool benchmarking. Recent developments in HLA peptidomics 12 for class I and II HLA molecules have been relevant for this goal, opening doors to evaluate the potential of deep learning tools for T cell epitope predictions. However, neoepitopes are rare and challenging to discover. Maximizing the probability of identifying clinically relevant neoepitopes requires the development of integrated frameworks to generate multiple method epitope prediction and advanced neoepitope quality metrics. Recent webservers such as HABIT (http://habit.evobiomed.com/) address this issue by automating HLA-binding prediction and the interpretation of the impact of amino acid variants in peptide-HLA binding. Future developments should include user-friendly webtools to allow automated treatment of next-generation sequencing (NGS) data, epitope prediction and neoepitope propensity quality analysis with interactive visualization (Figure 1) . Overall, the continued development in the field of ML-based epitope prediction is of great value for the rational design of T cell-based immunotherapies to cancer and other relevant diseases.
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